companies

AgomAb Therapeutics

Founded 2017
Employees 20+
Primary contact
Franklin Rooseveltlaan 348
9000 Ghent
Belgium
Links
https://agomab.com/
Sections
Founded through a collaboration between argenx and the University of Torino, Italy - Agomab is translating deep expertise in growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure and restore organ function. Combining new scientific insights with robust drug development and a long-term corporate vision, it is building a broad clinical pipeline of differentiated programs with disease-modifying potential in organ failure and fibrotic diseases.
Select partners: argenx, Lonza Pharma & Biotech, Università di Torino, Rutgers, VIB, Ku Leuven, Ghent University, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital de la Santa Creu i Sant Pau, Universitat de València.
Founded 2017
Employees 20+
Primary contact
Franklin Rooseveltlaan 348
9000 Ghent
Belgium
Links
https://agomab.com/
Sections

Funding 💰

Total $144M
Last round 🔗 $40.5M
Series B
July 13, 2022.
Select investors Pfizer Ventures, Boehringer Ingelheim Venture Fund, Redmile Group, AdBio partners, Andera Partners, V-Bio Ventures, Omnes Capital, Asabys Partners, Pontifax

Key people 🧑‍🤝‍🧑

Highlights ⭐

  • Growth factor biology expertise: Growth factor pathways have evolved to coordinate broad morphogenic and tissue repair programs, and can be leveraged to profoundly alleviate tissue injury, fibrotic remodeling, and organ failure. AgomAb leverages its deep understanding of growth factor biology and employ smart small molecules targeting the TGFβ pathway and agonistic antibodies targeting the HGF/MET pathway. 🔗
  • Broad pipeline: The company's pipeline consists of unique assets with a novel mode of actions against well-validated and potentially disease modifying targets with the aim to repair tissue injury, resolve fibrosis and restore organ function in patients with high unmet medical need. 🔗
  • Acquisition: At the end of 2021, Agomab Therapeutics acquired Spanish biotech Origo Biopharma, to combine their organ-restricted small molecule drug candidates targeting the transforming growth factor beta (TGF-β) pathway with its hepatocyte growth factor (HGF)-targeting programs. 🔗
  • Pan-European presence: In addition to its headquarters in Belgium, AgomAb also has offices in Spain (Barcelona and A Coruña) and Italy (Torino). 🔗
  • Solid team: During the years, AgomAb has managed to establish a great leadership team, hiring experts from across the industry. 🔗

Video ▶️

Awards & Recognitions 🏆

  • 2022 One of Fierce Biotech's "Fierce 15" Companies 🔗

Quotes 💬

“
Agomab is a highly innovative company with a pipeline that holds promise to help resolve fibrotic processes in a range of indications where there is very high unmet medical need. We are proud to support its mission to help deliver novel treatments for patients, and we look forward to bringing our global development capabilities and expertise to bear to help achieve it.
— Michael Vincent, MD, PhD, Senior Vice President and Chief Scientific Officer, Inflammation & Immunology, Pfizer 🔗
“
We are proud that the two years incubation of AgomAb led to this fantastic financing round. The AgomAb team continues to impress us with new data demonstrating the potential of this approach for fibrotic and degenerative diseases and we are very excited to be part of this journey.
— Katja Rosenkranz, Partner at V-Bio Ventures 🔗
Last update: January 13, 2023